Michel Briejer

Thuja Capital Management BV is a Venture Capital firm, a subsidiary of Thuja Capital Holding BV founded in 2006 by Harrold van Barlingen. Thuja Capital Management BV is headquartered in Utrecht.

FABPulous BV develops a handheld disposable plasma separation device with embedded in vitro diagnostic test capability. It offers ultra rapid plasma preparation platform that can make a defined dilution of plasma from a small volume of whole blood in seconds and integrated lateral flow IVD platform. The company’s tests provide diagnosis and benefit to the patient, as well as the healthcare sector, the insurance industry, governments and society in general. FABPulous was founded in 2008 and is headquartered in Maastricht, the Netherlands.

NightBalance BV develops and markets sensor-devices for the treatment of sleep apnea. It offers sleep position trainer, a small and light aid which can be worn around the chest with an ergonomic band. The firm's a sleep position sensor which gradually and comfortably trains patients using vibrations to not sleep on their back. The company was founded by Eline van Beest and Thijs van Oorschot in 2009 and is headquartered in The Hague, the Netherlands.

Alveron Pharma BV is a Dutch company that develops cyclodextrin-based drugs. The company is based in Nijmegen, Netherlands. The company was founded in 2019. Ben Nichols has been the CEO of the company since 2019.

EsoBiotec SA is a Belgian company that provides research and development on natural sciences and engineering. The company is based in Charleroi, Belgium. The company was founded in 2020 by Jean-Pierre Latere. Jean-Pierre Latere has been the CEO since 2020.

Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023.

FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016.

Nutrileads BV develops food ingredi?nts with a specific nutritional value. It identifies promising lead ingredients, develops sustainable and commercially viable production processes and initiates scientific and clinical programs to test the health effects. The company was founded in 2012 by Erik Dam and Ruud Albers and is headquartered in Wageningen, the Netherlands.

Cavadis BV discovers biomarkers for progression of atherosclerotic disease. The firm’s product series include pipeline, medical need, market potential and personalized medicine. The company was founded in 2007 by Ronald Nanninga and Oscar Schoots and is headquartered in Hilversum, the Netherlands.